CARSGEN-B(02171): The research results of Surjotiron's injection were displayed as a poster at the 2026 ASCO Annual Meeting.

date
08:25 01/06/2026
avatar
GMT Eight
CJ Medicine-B (02171) announced that the long-term analysis results of the sequential treatment of Shu Ray Ji Ao Lun Sai injection (product number: CT041, an autologous CAR-T cell therapy candidate targeting Claudin18.2 protein) in patients with advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) as first-line treatment will be presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, from 13:30 to 16:30 Central Daylight Time on May 30, 2026. For more details, please visit the company's official website https://www.carsgen.com.
CARSGEN-B (02171) announced that the long-term analysis study results of Satricabtagene autoleucel (product number: CT041, an autologous CAR-T cell therapy targeting Claudin18.2 protein) as sequential therapy after first-line treatment in patients with advanced gastric/esophageal junction adenocarcinoma (G/GEJA) will be presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026 from 13:30 to 16:30 Central Daylight Time. For more details, please visit the company's official website at https://www.carsgen.com. The abstract title presented at the 2026 ASCO Annual Meeting is "Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer a subgroup analysis".